290 related articles for article (PubMed ID: 21294597)
1. Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients.
Han K; Bies R; Johnson H; Capitano B; Venkataramanan R
Clin Pharmacokinet; 2011 Mar; 50(3):201-14. PubMed ID: 21294597
[TBL] [Abstract][Full Text] [Related]
2. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
[TBL] [Abstract][Full Text] [Related]
3. Voriconazole pharmacokinetics in liver transplant recipients.
Johnson HJ; Han K; Capitano B; Blisard D; Husain S; Linden PK; Marcos A; Kwak EJ; Potoski B; Paterson DL; Romkes M; Venkataramanan R
Antimicrob Agents Chemother; 2010 Feb; 54(2):852-9. PubMed ID: 19933807
[TBL] [Abstract][Full Text] [Related]
4. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients.
Han K; Capitano B; Bies R; Potoski BA; Husain S; Gilbert S; Paterson DL; McCurry K; Venkataramanan R
Antimicrob Agents Chemother; 2010 Oct; 54(10):4424-31. PubMed ID: 20679503
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.
Wilhelm AJ; de Graaf P; Veldkamp AI; Janssen JJ; Huijgens PC; Swart EL
Br J Clin Pharmacol; 2012 Apr; 73(4):553-63. PubMed ID: 21988410
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.
Purkins L; Wood N; Ghahramani P; Greenhalgh K; Allen MJ; Kleinermans D
Antimicrob Agents Chemother; 2002 Aug; 46(8):2546-53. PubMed ID: 12121931
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of voriconazole in adults.
Hope WW
Antimicrob Agents Chemother; 2012 Jan; 56(1):526-31. PubMed ID: 22064545
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation.
Benkali K; Rostaing L; Premaud A; Woillard JB; Saint-Marcoux F; Urien S; Kamar N; Marquet P; Rousseau A
Clin Pharmacokinet; 2010 Oct; 49(10):683-92. PubMed ID: 20818834
[TBL] [Abstract][Full Text] [Related]
9. A population pharmacokinetic model of ciclosporin applicable for assisting dose management of kidney transplant recipients.
Falck P; Midtvedt K; Vân Lê TT; Storehagen L; Holdaas H; Hartmann A; Asberg A
Clin Pharmacokinet; 2009; 48(9):615-23. PubMed ID: 19725595
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.
Zhao W; Cella M; Della Pasqua O; Burger D; Jacqz-Aigrain E;
Br J Clin Pharmacol; 2012 Apr; 73(4):641-50. PubMed ID: 21988586
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?
Brooks E; Tett SE; Isbel NM; Staatz CE
Clin Pharmacokinet; 2016 Nov; 55(11):1295-1335. PubMed ID: 27138787
[TBL] [Abstract][Full Text] [Related]
12. Ciclosporin population pharmacokinetics and Bayesian estimation in thoracic transplant recipients.
Fruit D; Rousseau A; Amrein C; Rollé F; Kamar N; Sebbag L; Redonnet M; Epailly E; Marquet P; Prémaud A
Clin Pharmacokinet; 2013 Apr; 52(4):277-88. PubMed ID: 23400901
[TBL] [Abstract][Full Text] [Related]
13. Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients.
Benkali K; Prémaud A; Picard N; Rérolle JP; Toupance O; Hoizey G; Turcant A; Villemain F; Le Meur Y; Marquet P; Rousseau A
Clin Pharmacokinet; 2009; 48(12):805-16. PubMed ID: 19902988
[TBL] [Abstract][Full Text] [Related]
14. Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients.
Djebli N; Rousseau A; Hoizey G; Rerolle JP; Toupance O; Le Meur Y; Marquet P
Clin Pharmacokinet; 2006; 45(11):1135-48. PubMed ID: 17048977
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies.
Karlsson MO; Lutsar I; Milligan PA
Antimicrob Agents Chemother; 2009 Mar; 53(3):935-44. PubMed ID: 19075073
[TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent.
Purkins L; Wood N; Greenhalgh K; Eve MD; Oliver SD; Nichols D
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):2-9. PubMed ID: 14616407
[TBL] [Abstract][Full Text] [Related]
17. Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients.
Saint-Marcoux F; Marquet P; Jacqz-Aigrain E; Bernard N; Thiry P; Le Meur Y; Rousseau A
Clin Pharmacokinet; 2006; 45(9):905-22. PubMed ID: 16928152
[TBL] [Abstract][Full Text] [Related]
18. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections.
Wang T; Chen S; Sun J; Cai J; Cheng X; Dong H; Wang X; Xing J; Dong W; Yao H; Dong Y
J Antimicrob Chemother; 2014 Feb; 69(2):463-70. PubMed ID: 24084636
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients.
Hennig S; Wainwright CE; Bell SC; Miller H; Friberg LE; Charles BG
Clin Pharmacokinet; 2006; 45(11):1099-114. PubMed ID: 17048974
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels.
Gotta V; Widmer N; Montemurro M; Leyvraz S; Haouala A; Decosterd LA; Csajka C; Buclin T
Clin Pharmacokinet; 2012 Mar; 51(3):187-201. PubMed ID: 22339450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
